Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease.

"Declarations Conflict of interestPM served as speaker and/or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Baxter, and Tillotts Pharma. HS served as speaker and/or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Gilead, and Tillotts Pharma. DA served as speaker and/or advisory board member for AbbVie, Janssen, and Takeda. FH is an employee of Janssen Cilag AB, Sweden. OO has been PI on projects at Karolinska Institutet, partly financed by investigator-initiated grants from Janssen and Ferring, and Karolinska Institutet has received fees for lectures and participation on advisory boards from Janssen, Ferring, Takeda, and Pfizer. OO also reports a grant from Pfizer in the context of a national safety monitoring program. JH served as speaker and/or advisory board member for AbbVie, Celgene, Celltrion, Dr. Falk Pharma and the Falk Foundation, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz/Novartis, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD, and Takeda. Ethical approvalThis study was performed in line with the principles of the Declaration of Helsinki. All study participants signed an informed consent authorizing the use of data collected in this study. This project was approved by the Regional Ethical Review Board in Linköping, Sweden (2017–290-31). Conflict of interest PM served as speaker and/or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Baxter, and Tillotts Pharma. HS served as speaker and/or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Gilead, and Tillotts Pharma. DA served as speaker and/or advisory board member for AbbVie, Janssen, and Takeda. FH is an employee of Janssen Cilag AB, Sweden. OO has been PI on projects at Karolinska Institutet, partly financed by investigator-initiated grants from Janssen and Ferring, and Karolinska Institutet has received fees for lectures and participation on advisory boards from Janssen, Ferring, Takeda, and Pfizer. OO also reports a grant from Pfizer in the context of a national safety monitoring program. JH served as speaker and/or advisory board member for AbbVie, Celgene, Celltrion, Dr. Falk Pharma and the Falk Foundation, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz/Novartis, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD, and Takeda."

"Funding Open access funding provided by Karolinska Institute. This work was supported by Janssen Cilag AB, Sweden."